Drug Development
CepTor executes Letter of Intent with Ferring for late-stage product targeted for Phase 2B trials
Published in Medical Letter on the CDC and FDA, October 22nd, 2006
CepTor Corporation (CEPO), a biopharmaceutical company focusing on cell-targeted therapeutic products for neuromuscular and neurodegenerative diseases, announced that it has signed a Letter of Intent (LOI) with Ferring International Center, S.A. in which Ferring plans to divest and CepTor plans to purchase recombinant human copper zinc superoxide dismutase (r-h CuZnSOD or SOD) for prevention of chronic respiratory morbidity in premature newborns.
Upon and subject to completion of due diligence culminating in an agreement with the Food and Drug Administration (FDA) on the endpoints for a phase 2B clinical trial, CepTor will pay Ferring an exclusive option payment. CepTor...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Food Safety
Determining microbiological criteria for lot rejection due to food safety is described - Food Safety
High pressure and moderate temperatures inactivate Clostridium botulinum spores - HIV/AIDS Therapy
Tenofovir disoproxil fumarate is linked to hypophosphatemia in patients receiving HAART - Tick-Borne Disease
Rickettsia massiliae was isolated from Rhipicephalus sanguineus ticks in Arizona - Varicella-Zoster Virus
New mosaic subgenotype of varicella-zoster virus has been identified in U.S. - Addiction Medicine
Chicago deaths from fentanyl-laced heroin overdoses could be reduced by medical treatment - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
